Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

EPT Disclosure-Amendment

14th Apr 2010 11:41

RNS Number : 1752K
Credit Suisse Securities (Eur) Ltd
14 April 2010
 

FORM 38.5 (a)

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITH RECOGNISED INTERMEDIARY STATUS

DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(a) of the Takeover Code)

AMENDMENT

 

The amendment in position represents the effect of a late booked trade, book transfer and/or cancel/correct activity

 

1. KEY INFORMATION

Name of exempt principal trader

Credit Suisse Securities (Europe) Limited

Company dealt in

Ark Therapeutics Group PLC

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ordinary Shares

Date of dealing

12-Apr-2010

2. DEALINGS (Note 2)

(a) Purchases and sales

Total number of securities purchased

Highest price paid (Note 3)

Lowest price paid (Note 3)

130000

0.115 (GBP)

0.10 (GBP)

 

Total number of securities sold

Highest price received (Note 3)

Lowest price received (Note 3)

130000

0.115 (GBP)

0.10 (GBP)

(b) Derivatives transactions (other than options)

Product name, e.g. CFD

Long/short (Note 4)

Number of securities (Note 5)

Price per unit (Note 3)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

(ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 3)

3. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Date of disclosure

14-Apr-2010 08:10:58

Contact name

Eliades,Vassilis D/Simon Crawley

Telephone number

+44 7810 360119

Name of offeree/offeror with which connected

Ark Therapeutics Group PLC

Nature of connection (Note 6)

ADVISOR

Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMSFSFSLFSSELL

Related Shares:

PVG.L
FTSE 100 Latest
Value8,417.34
Change2.09